This federal Project Grant award of $714,934.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research conducted by the Henry Ford Health System in Detroit, Michigan to investigate the link between pancreatic neoplasia and carcinoma. The project aims to transform healthcare for military service members and the broader public by advancing innovative and impactful biomedical research across diverse medical disciplines. The...
The Defense Health Agency awarded a $523,663 Project Grant to the Henry Ford Health System - doing business as Henry Ford Hospital, a non-profit hospital in Detroit, Michigan. The grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports research to investigate the NETRIN G1 ligand as a new immunomodulatory target and early biomarker in pancreatic cancer. The project will be conducted from August 1, 2023 to July 31, 2026. Henry Ford Health System has...
The Department of the Army Medical Command awarded a $292,260 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Henry Ford Health System in Detroit, Michigan. The grant, with a performance period from July 1, 2025 to June 30, 2028, will fund research to investigate the link between pancreatic neoplasia and carcinoma. As a non-profit integrated healthcare provider and research organization, Henry Ford Health System will leverage its medical research...
The Henry Ford Health System was awarded a $615,782 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 15, 2022 to July 14, 2025 to investigate paracrine pathways contributing to the growth and invasion of neurofibromas and the role of the cellular microenvironment. Through this research, the awardee aims to advance understanding of medical solutions for neurofibromas,...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $467,742 Project Grant to the Regents of the University of Michigan to optimize a risk stratification model for ovarian cancer. The award will support research activities from September 1, 2024 through August 31, 2026. The University of Michigan, a top public research institution, has extensive experience conducting federal research and development projects for agencies such as the...
This $924,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Wayne State University to target dual-specificity phosphatase 1 in platinum resistance in ovarian cancer. The award, which runs from July 1, 2024 to June 30, 2028, will enable Wayne State to conduct innovative scientific studies to improve treatment options and outcomes for this challenging form of cancer, which disproportionately impacts...
Henry Ford Hospital will receive $1.1 million from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to conduct the project "TRIBBLES 2, A NOVEL TARGET FOR THERAPY OF ENZALUTAMIDE-RESISTANT NEUROENDOCRINE PROSTATE CANCER" from September 1, 2022 through August 31, 2025. This project aims to investigate medical solutions for prostate cancer through basic, applied, and advanced biomedical research focused on developing new...
This $1,248,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support the "RARE-CANCER COMMONS: A HUB FOR ACCELERATING INDIVIDUALIZED RARE CANCER THERAPY THROUGH INTEGRATION OF SINGLE-CELL AND CLINICAL GENOMICS DATA" research initiative at the University of Michigan. The project, running from November 1, 2024 to October 31, 2027, will leverage the University's extensive research capabilities to...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...